Navigation auf


UZH Innovation Hub

MUVON Therapeutics: Phase II clinical trial started

Deana Mohr
Photo: Deana Mohr


Former MedTech UZH Entrepreneur fellow Dr. Deana Mohr  and her UZH spin-off Muvon Therapeutics announce first patient enrolled in phase II clinical study.


Muvon Therapeutics AG  is an innovative clinical-stage biotechnology company, co-founded by former MedTech UZH Entrepreneur fellow Dr. Deana Mohr. On October 27, 2022, Muvon Therapeutics announced that the first patient with Stress Urinary Incontinence has been enrolled as part of the planned Phase II clinical trial (SUISSE MPC 2-Study) using its novel proprietary cell therapy platform.


This is a randomized blinded clinical study. The goal of the study is to evaluate the safety and efficacy of a low and high dose of autologous skeletal muscle precursor cell injections. Those injections are directly applied  into the urethral sphincter muscle of women living with stress urinary incontinence (SUI). Like this, strength and function of the sphincter muscle shall be restored. According to Deana Mohr, the procedure is minimally invasive and increases patient tolerability.

An earlier Phase I study  demonstrated the safety, feasibility and potential efficacy. No serious adverse events or unexpected adverse events were observed.


Congratulations to Dr. Deana Mohr and her team for this promising achievement!


Innovation Hub

Weiterführende Informationen

MUVON Therapeutics

Regain control with personalized muscle regeneration